RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection

EP: 1.Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

EP: 2.Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

EP: 3.Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC

Now Viewing

EP: 4.RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection

EP: 5.Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment

EP: 6.Navigating RCC Progression: Optimizing Treatment Sequence After the First Line

EP: 7.Post-Immunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies

EP: 8.Emerging Therapies in RCC: Shaping Future Treatment Sequences

EP: 9.RCC Treatment Evolution: Expert Perspectives on the Evolving Landscape and Advances From ASCO GU 2025

Video content above is prompted by the following:

• When you’re evaluating treatment options for your advanced RCC patients today, what key factors drive your decision between the IO/IO approach with ipilimumab/nivolumab vs the various IO/TKI combinations like pembrolizumab/lenvatinib, pembrolizumab/axitinib, nivolumab/cabozantinib, or avelumab/axitinib? How do you weigh patient characteristics, risk stratification, PD-L1 status, and other clinical features in this decision?
• Dr Barata asks Dr Beckermann:Briefly discuss your perspective on the patient experience for patients undergoing IO/TKI regimens and explore strategies for their mitigation and management.
• Comment on how patterns of hepatoxicity differ across trials and discuss your general approach to management.